Research has shown some common risk factors between T2DM and AD: higher cholesterol[9], dis-metabolism, degeneration[9], myloid β (Aβ) deposition[9], Glycogen synthesis kinase 3(GSK3), and τ protein phosphorylation[10], cardiovascular disease, oxidative stress[2], inflammation[2], ApoE4[11], apoptosis etc. A new finding shows that treatment with GLP-1 beneficially affects a number of the therapeutic targets associated with AD. This evidence concerns the gene GLP1R and Alzheimer disease.